Good overview on Mounjaro and Obesity https://erictopol.substack.com/p/the-new-obesity-breakthrough-drugs

Lilly Press Release on Surmont-1 Results on Weight Loss

Once Weekly Treatment for Obesity Trial (Surmont-1)

Editorial in NEJM on Surmont-1 Study

Tirzepatide (Mounjaro) is an imbalanced and biased dual GIP and GLP-1 receptor agonist
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526454/

The Science Behind How We Really Burn Calories – Scientific American https://apple.news/AcAITuGVQQ4y124vrqJPHBQ

Mounjaro Mechanism of Action